SCHEMBL277160

SCHEMBL277160

[CH2][Si](C)(C)c1ccccc1-c1ccc2ccc3cccc4ccc1c2c34

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.42
HSD17B10 Q99714 5/20 0.42
HPGD P15428 5/20 0.42
TSHR P16473 4/20 0.42
CYP3A4 P08684 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
CYP1A2 P05177 3/20 0.40
ERBB2 P04626 1/20 0.40
FYN P06241 1/20 0.40
MAOA P21397 1/20 0.40
ACHE P22303 1/20 0.40
AHR P35869 1/20 0.40
THRB P10828 1/20 0.38
MAPK1 P28482 3/20 0.36
CASP1 P29466 2/20 0.36
CASP7 P55210 2/20 0.36
TP53 P04637 1/20 0.36
HIF1A Q16665 1/20 0.36
CYP1A1 P04798 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5334139 0.78 ALDH1A1 (0.56) ALDH1A1HSD17B10HPGDTSHRCYP3A4
SCHEMBL3979024 0.77 CYP1A2 (0.40) ALDH1A1HSD17B10HPGDTSHRCYP3A4
SCHEMBL2956150 0.76 ALDH1A1 (0.64) ALDH1A1HSD17B10HPGDTSHRCYP3A4
SCHEMBL29413360 0.76 ALDH1A1 (0.61) ALDH1A1HSD17B10HPGDTSHRCYP3A4
SCHEMBL2124728 0.76 ALDH1A1 (0.61) ALDH1A1HSD17B10HPGDTSHRCYP3A4
SCHEMBL29814212 0.76 ALDH1A1 (0.61) ALDH1A1HSD17B10HPGDTSHRCYP3A4
SCHEMBL441488 0.75 HSD17B10 (0.56) ALDH1A1HSD17B10HPGDTSHRCYP3A4
SCHEMBL443350 0.74 CYP1A2 (0.60) ALDH1A1HSD17B10HPGDTSHRCYP3A4
SCHEMBL27602345 0.74 ALDH1A1 (0.59) ALDH1A1HSD17B10HPGDTSHRCYP3A4
SCHEMBL276464 0.74 HPGD (0.39) ALDH1A1HSD17B10HPGDTSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2116521-B1 PROCESS FOR PRODUCING FULLERENE DERIVATIVE JAPAN SCIENCE & TECH AGENCY (JP) 2016-07-06 EP disclosed
US-8134019-B2 Process for producing fullerene derivative JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2012-03-13 US disclosed
US-20100048934-A1 PROCESS FOR PRODUCING FULLERENE DERIVATIVE JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2010-02-25 US disclosed
EP-2116521-A1 PROCESS FOR PRODUCING FULLERENE DERIVATIVE Japan Science and Technology Agency (JP) 2009-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048934-A1 PROCESS FOR PRODUCING FULLERENE DERIVATIVE INF2, EIF4B, C9 ALDH1A1 1723/4885HSD17B10 1514/4885HPGD 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.